On 8 July 2024, Genentech announced that the FDA has approved the relaunch of Susvimo®, a refillable ocular implant containing a specialised formulation of ranibizumab, which is used for treating nAMD.
The FDA first approved Susvimo® in October 2021. However, in October 2022, Genentech launched a voluntary recall after test results showed some implants did not perform to Genentech’s standards. Genentech has now updated the Susvimo® implant and refill needle, and reports that testing confirms the performance standards are met.